2|10000|Public
40|$|Deoxycytidylate deaminase, catalyzing the {{conversion}} of dCMP to dUMP, is an important enzyme in the de novo syn-thesis of thymidine nucleotides. It also {{may be involved in}} the action, as well as the metabolism of anticancer agents. Recently, several L- and D-configuration pyrimidine deoxynucleoside ana-logs were found to be potent antiviral and antitumor agents. Their interaction with dCMP deaminase as a monophosphate or a triphosphate metabolite is not clear. These include D-nucleoside analogs such as -D- <b>2,</b> <b>3</b> <b>-dideoxycytidine</b> (ddC), - 2 -fluoro- 5 -methyl-arabinofuranosyluracil (FMAU), 3 -azido- 2, 3 -dideoxythy-midine (AZT), and 2, 3 -didehydro- 2, 3 -dideoxythymidine (D 4 T) as well as L-nucleoside analogs such as -L-dioxolane-cytidin...|$|E
40|$|Nucleoside analogs are {{modified}} nucleosides used {{in treatment}} {{of cancer and}} viral infections. They are dependent on intracellular phosphorylation to be pharmacologically active. Deoxyribonucleoside kinases catalyze the rate-limiting step in the phosphorylation of many clinically used nucleoside analogs. Human cells contain four distinct deoxyribonucleoside kinases that have partially overlapping substrate specificities for both naturally occurring deoxyribonucleosides as well as nucleoside analogs. The deoxycytidine analog <b>2,</b> <b>3</b> <b>-dideoxycytidine</b> (ddC) {{has been used for}} treatment of human immunodeficiency virus (HIV) infections. ddC causes delayed toxicity, due to mitochondrial DNA (mtDNA) depletion, when cells are exposed to the drug at low concentration for prolonged periods of time. CEM T-lymphoblast cell lines resistant to the delayed toxicity of ddC were generated and studied. Although the cells were resistant to mtDNA depletion they had a retained anti-HIV activity of ddC. The ddC resistant cells were shown to have slightly increased levels of mtDNA and decreased mRNA expression of deoxycytidine kinase and thymidine kinase 2. Mitochondria are the main providers of energy for cells and these organelles have a separate genome distinct from the nuclear genome. The mitochondrial genome is dependent on the mitochondrial deoxyribonucleoside kinases for normal DNA replication. Inherited deficiency of either of the two mitochondrial deoxyribonucleoside kinases deoxyguanosine kinase (dGK) and thymidine kinase 2 (TK 2), causes mtDNA depletion in patients. In order to understand the molecular mechanism of mtDNA depletion due to TK 2 deficiency, a Tk 2 deficient mouse strain was generated and characterized. The Tk 2 deficient mice showed growth retardation, severe hypothermia and a reduced life span. They also exhibited mtDNA depletion in multiple organs. It was concluded that TK 2 has a major role in supplying deoxyribonucleotides for mtDNA replication and that other pathways of deoxyribonucleotide synthesis cannot compensate for the loss of this enzyme. TK 2 phosphorylates several nucleoside analogs that are also substrates of other deoxyribonucleoside kinases. To elucidate the role of TK 2 mediated phosphorylation in the cytotoxic effects of nucleoside analogs, a human fibroblast cell line with partial TK 2 deficiency was studied. A recombinant enzyme with the same mutation found in the TK 2 -deficient cells was also investigated in order to obtain further insights into the mechanisms of TK 2 deficiency. It was concluded that the loss of TK 2 activity did not alter the cells sensitivity to nucleoside analogs and that TK 2 phosphorylation may be less important, compared to other deoxyribonucleoside kinases, for the cytotoxic effects of these compounds. The deoxyribonucleoside kinase of the fruit fly Drosophila melanogaster (Dm-dNK) is a multisubstrate enzyme that phosphorylates pyrimidine and purine deoxyribonucleosides as well as several anticancer and antiviral nucleoside analogs. The broad substrate specificity together with the high catalytic rate makes it an interesting candidate gene for suicide gene therapy. In order to understand the determinants of the substrate specificity of the enzyme and to find Dm-dNK mutants with improved kinetic properties for application in suicide gene therapy, we performed site directed mutagenesis on the enzyme. It was shown that the mutants showed partial or complete loss of activity compared with the wild type enzyme in terms of thymidine phosphorylation. This decreased phosphorylation efficiency supports their importance for substrate binding...|$|E
5000|$|... <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3,...|$|R
5000|$|... <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 11, <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 11, <b>2,</b> <b>3,</b> <b>2,</b> 19, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 11, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 19, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 19, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 13, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 11, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 11, <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 0, ...|$|R
5000|$|... <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 2, 7, <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 17, <b>3,</b> <b>2,</b> <b>2,</b> 5, <b>3,</b> <b>2,</b> 5, 2, <b>2,</b> 229, <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> 5, <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> <b>3,</b> 37, <b>2,</b> <b>3,</b> 5, 58543, <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>3,</b> 4663, 54517, 17, <b>3,</b> <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> 2, 47, 61, 19, ...|$|R
5000|$|... <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 5, 2, 2, 2, <b>2,</b> 7, 5, <b>3,</b> <b>2,</b> <b>3,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 2, 5, 2, 2, 2, 7, 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> 7, 7, <b>2,</b> <b>3,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 2, 2, 11, 5, 2, 2, 5, <b>2,</b> <b>2,</b> <b>3,</b> 7, <b>3,</b> <b>2,</b> 2, ...|$|R
5000|$|... 0, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 9, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 13, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 15, <b>2,</b> 9, <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> ...|$|R
5000|$|... <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 11, <b>2,</b> <b>3,</b> 0, 7, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 7, 0, <b>3,</b> <b>2,</b> 5, <b>2,</b> 11, <b>2,</b> <b>3,</b> <b>2,</b> 19, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 11, <b>2,</b> 5, 0, <b>3,</b> <b>2,</b> 5, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 19, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 19, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> ...|$|R
5000|$|... 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 1, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 1, <b>2,</b> <b>3,</b> <b>3,</b> 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 1, 1, 1, <b>2,</b> <b>3,</b> 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 1, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 1, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 1, <b>2,</b> <b>3,</b> 3, 1, 1, 1, <b>2,</b> <b>3,</b> 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 1, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 1, <b>2,</b> <b>3,</b> <b>3,</b> 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> 1, <b>2,</b> <b>3,</b> 3,...|$|R
5000|$|... <b>2</b> 1 <b>3</b> <b>3</b> <b>2</b> 1 <b>3</b> <b>3</b> <b>2</b> 1 1 1 <b>3</b> 1 <b>2</b> <b>3</b> 1 3 3 1 1 3 3 1 1 1 <b>2</b> <b>3</b> <b>2</b> <b>3</b> 1 1 <b>2</b> <b>3</b> 1 1 <b>3</b> <b>2</b> 1 <b>2</b> <b>3</b> <b>3</b> 1 <b>2</b> <b>2</b> <b>3</b> <b>3</b> 1 1 <b>2</b> <b>3</b> <b>2</b> <b>2</b> <b>3</b> ...|$|R
5000|$|... 1, <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 6, <b>3,</b> 5, <b>2,</b> 2, 2, <b>2,</b> 7, 5, <b>3,</b> <b>2,</b> <b>3,</b> 5, <b>2,</b> 5, <b>2,</b> 6, <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 2, 6, 5, 2, 5, 2, 2, 2, 19, 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 6, <b>3,</b> 7, 7, 6, <b>3,</b> 5, <b>2,</b> 6, 5, <b>3,</b> <b>3,</b> <b>2,</b> 5, 17, 10, <b>2,</b> <b>3,</b> 10, <b>2,</b> <b>2,</b> <b>3,</b> 7, 6, <b>2,</b> 2, ...|$|R
5000|$|... 0, 1, 1, 2, 1, <b>2,</b> <b>2,</b> <b>3,</b> 1, <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> 4, 1, <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> 4, <b>2,</b> <b>3,</b> 3, 4, 3, 4, 4, 5, ...|$|R
5000|$|... <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>3,</b> 0, <b>2,</b> 17, <b>2,</b> 5, <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 19, <b>3,</b> <b>3,</b> <b>2,</b> 5, <b>3,</b> 0, 7, <b>3,</b> <b>2,</b> 5, <b>2,</b> 7, 0, <b>3,</b> 13, 313, <b>2,</b> 13, <b>3,</b> 349, <b>2,</b> <b>3,</b> <b>2,</b> 5, 5, 19, 2, 127, 19, 0, <b>3,</b> 4229, <b>2,</b> 11, <b>3,</b> 17, 7, <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>3,</b> 5, 0, 19, <b>2,</b> 19, 5, <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> ...|$|R
5000|$|... <b>3,</b> <b>2,</b> <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> 5, 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> 7, <b>2,</b> 17, <b>2,</b> <b>3,</b> <b>3,</b> 11, <b>2,</b> <b>3,</b> 11, 0, <b>3,</b> 7, <b>2,</b> 109, <b>2,</b> 5, <b>3,</b> 11, 31, 5, <b>2,</b> <b>3,</b> 53, 17, <b>2,</b> 5, 2, 103, 7, 5, <b>2,</b> 7, 1153, <b>3,</b> 7, 21943, <b>2,</b> <b>3,</b> 37, 53, <b>3,</b> 17, <b>2,</b> 7, <b>2,</b> <b>3,</b> 0, 19, 7, <b>3,</b> <b>2,</b> 11, <b>3,</b> 5, <b>2,</b> ... (notice this OEIS {{sequence}} {{does not}} allow [...] ) ...|$|R
5000|$|... 4, 4, 3, 3, 3, 4, <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> 3, 4, <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> 3, 4, <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> 4, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> 3, 4, ...|$|R
5000|$|... 2, <b>2,</b> 1, 1, <b>3,</b> 1, <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> 1, 1, 1, 2, 2, 2, 1, 1, 1, <b>3,</b> <b>3,</b> <b>2,</b> 1, <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> 1, 3, 1, 1, 1, 3, 3, 3, 1, 1, <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3, 1, 1, 3, 3, 3, 1, 1, 1, 3, <b>3,</b> 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 1, 1, 1, <b>3,</b> 1, <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> 2, 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> 2, 2, 1, 2, 1, 1, 1,...|$|R
5000|$|... 0, 1, 1, 1, 1, 1, 1, 2, 1, 1, <b>2,</b> <b>3,</b> <b>2,</b> 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 2, 2, 1, <b>2,</b> 4, <b>2,</b> <b>3,</b> <b>2,</b> 2, 2, <b>2,</b> 1, 1, <b>3,</b> 4, <b>2,</b> 4, 4, <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> 2, 4, 2, 4, 4, <b>2,</b> 5, <b>3,</b> 4, <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> 4, <b>2,</b> <b>2,</b> <b>3,</b> 4, <b>2,</b> 4, 4, 4, <b>3,</b> <b>2,</b> <b>3,</b> 5, 4, <b>2,</b> 1, ...|$|R
40|$|Tubacin {{prevents}} neuronal migration {{defects and}} epileptic activity caused by rat Srpx 2 silencing in utero Manal Salmi, 1, <b>2,</b> <b>3,</b> 4, * Nadine Bruneau, 1, <b>2,</b> <b>3,</b> 4, * Jennifer Cillario, 1, <b>2,</b> <b>3,</b> 4, * Natalia Lozovaya, 1, <b>2,</b> <b>3,</b> 5 Annick Massacrier, 1, <b>2,</b> <b>3,</b> 4 Emmanuelle Buhler, 1, <b>2,</b> <b>3,</b> 4, 6 Robin Cloarec, 1, <b>2,</b> <b>3,</b> 4 Timur Tsintsadze, 1, <b>2,</b> <b>3,...</b>|$|R
5000|$|... 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 4, 4, 4, 1, 1, 1, 2, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 3, 4, 4, 4, 4, 1, <b>2,</b> <b>3,</b> 4, 4, 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 4, 4, 4, 1, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 4, 4, 4, 4, 1, 1, 1, 1, 2, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 3, 4, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 3, 4, 4, 4, 4, 1, <b>2,</b> <b>3,</b> 3, 4, 4, 1, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 3, 4, 4, 4, 4, 1, 1, 1, 1, <b>2,</b> <b>3,</b> 4, 1, 1,...|$|R
40|$|Contents 2. 1 Introduction 2. 2 Drug Distribution 2. 2. 1 Introduction to drug {{distribution}} 2. 2. 2 Protein binding <b>2.</b> <b>2.</b> <b>3</b> Factors that modify protein binding and {{drug distribution}}? 2. 2. 4 Blood brain barrier 2. 2. 5 Volume of distribution <b>2.</b> <b>3</b> Drug Metabolism <b>2.</b> <b>3.</b> 1 Introduction <b>2.</b> <b>3.</b> <b>2</b> Phase I <b>2.</b> <b>3.</b> <b>2.</b> 1 Induction <b>2.</b> <b>3.</b> <b>2.</b> <b>2</b> Inhibition <b>2.</b> <b>3.</b> 3 Phase II: Conjugation <b>2.</b> <b>3.</b> 4 First pass metabolism and bioavailability <b>2.</b> <b>3.</b> 5 Prodrugs <b>2.</b> <b>3.</b> 6 Pharmacologically active metabolites <b>2.</b> <b>3.</b> 7 Pharmacological toxic metabolites 2. 4 Drug Elimination 2. 4. 1 Introduction 2. 4. 2 Kidney 2. 4. 2. 1 Introduction 2. 4. 2. 2 Secretion and Reabsorption <b>2.</b> 4. <b>2.</b> <b>3</b> Renal insufficiency <b>2.</b> 4. <b>3</b> Other routes of excretion 2. 5 Blood levels 2. 5. 1 Elimination half-life 2. 5. 2 First and zero order kinetics <b>2.</b> 5. <b>3</b> Minimum effective and steady-state concentrations 2. 5. 4 Maintenance doses and loading dose...|$|R
5000|$|... 1, 1, <b>2,</b> 1, <b>2,</b> <b>3,</b> 1, <b>2,</b> <b>3,</b> 4, 1, <b>2,</b> <b>3,</b> 4, 5, 1, <b>2,</b> <b>3,</b> 4, 5, 6, ...|$|R
40|$|In {{this paper}} we first {{investigate}} for what positive integers a,b,c every nonnegative integer n {{can be represented}} as x(ax+ 1) +y(by+ 1) +z(cz+ 1) with x,y,z integers. We show that (a,b,c) can be either of the following seven triples: (1, <b>2,</b> <b>3),</b> (1, <b>2,</b> 4), (1, 2, 5), (2, 2, 4), (2, <b>2,</b> 5), (<b>2,</b> <b>3,</b> <b>3),</b> (<b>2,</b> <b>3,</b> 4), and conjecture that any triple (a,b,c) among (2, <b>2,</b> 6), (<b>2,</b> <b>3,</b> 5), (<b>2,</b> <b>3,</b> 7), (<b>2,</b> <b>3,</b> 8), (<b>2,</b> <b>3,</b> 9), (<b>2,</b> <b>3,</b> 10) also has the desired property. For integers 0 2, we prove that any nonnegative integer can be represented as x(ax+b) +y(ay+c) +z(az+d) with x,y,z integers, {{if and only if}} the quadruple (a,b,c,d) is among (<b>3,</b> 0, 1, <b>2),</b> (<b>3,</b> 1, 1, <b>2),</b> (<b>3,</b> 1, <b>2,</b> <b>2),</b> (<b>3,</b> 1, <b>2,</b> <b>3),</b> (4, 1, <b>2,</b> <b>3).</b> Comment: 9 pages, final published versio...|$|R
5000|$|Kotekan 1 <b>2</b> <b>3</b> 1 <b>2</b> <b>3</b> 1 <b>2</b> <b>3</b> 1 <b>2</b> <b>3</b> 1 <b>2</b> <b>3</b> 1 etc... Pokok 1 [...] [...] [...] 2 [...] [...] [...] 3 [...] [...] [...] 1 [...] [...] [...] etc...|$|R
5000|$|... 2, 15, 2, ?, <b>2,</b> 11, 10, <b>3,</b> <b>2,</b> ?, <b>2,</b> 5, ?, <b>3,</b> <b>2,</b> 13, <b>2,</b> ?, ?, <b>3,</b> <b>2,</b> ?, 9, 7, ?, ?, <b>2,</b> ?, <b>2,</b> 7, ?, <b>3,</b> 5, 25, <b>2,</b> 323, 226, <b>3,</b> <b>2,</b> ?, <b>2,</b> 5, ?, <b>3,</b> <b>2,</b> 31, 85, 7, ?, ?, <b>2,</b> ?, 14, 5, ?, <b>3,</b> <b>2,</b> ?, 2, ?, ?, 15, 10, ?, ...|$|R
25|$|For example, {{suppose the}} data values are 0, <b>3,</b> 4, 1, <b>2,</b> <b>3,</b> 0, <b>2,</b> 1, <b>3,</b> <b>2,</b> 0, <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> <b>3,</b> 999.|$|R
5000|$|... 2, 2, 1093, 11, 2, 2, 66161, 5, <b>2,</b> <b>2,</b> <b>3,</b> 71, <b>2,</b> 2, 29, 29131, <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> 2, 13, 13, <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> 2, 7, 7, <b>2,</b> <b>2,</b> 46145917691, <b>3,</b> <b>2,</b> 2, 17, 8039, 2, 2, 23, 5, <b>2,</b> <b>2,</b> <b>3,</b> ...|$|R
5000|$|... (inSkill (apply 'plus '(1 <b>2</b> <b>3</b> 4 5 6 7)))(inScheme (apply plus '(1 <b>2</b> <b>3</b> 4 5 6 7)))(inSkill (apply 'plus 1 <b>2</b> <b>3</b> '(4 5 6 7)))(inScheme (apply plus 1 <b>2</b> <b>3</b> '(4 5 6 7)))(inSkill (funcall 'plus 1 <b>2</b> <b>3</b> 4 5 6 7)))(inScheme (funcall plus 1 <b>2</b> <b>3</b> 4 5 6 7))) ...|$|R
40|$|The {{behavioural}} and anticonvulsant {{effects of}} several 1 -aryl- 3, 5 -dihydro- 4 H- <b>2,</b> <b>3</b> -benzodiazepin- 4 -ones (<b>2,</b> <b>3</b> -BZs) and of 11 b-aryl- 7, 11 -dihydro- <b>3</b> -phenyl[1, <b>2,</b> 4]oxadiazolo[5, 4 -a][2, 3]benz odiazepin- 6 -ones (<b>2,</b> <b>3</b> -OBZs) were studied after intraperitoneal (i. p.) administration in DBA/ 2 mice, a strain genetically susceptible to sound-induced seizures. The seizures were evoked {{by means of}} auditory stimulation (109 dB, 12 - 16 kHz) in animals placed singly under a hemispheric Perspex dome. The <b>2,</b> <b>3</b> -benzodiazepines studied after 30 min pretreatment were generally less potent than the related derivative 1 -(4 -aminophenyl) - 4 -methyl- 7, 8 -methylenedioxy- 5 H- <b>2,</b> <b>3</b> -benzodiazepine hydrochloride (GYKI 52466) except 3, 5 -dihydro- 7, 8 -dimethoxy- 1 -phenyl- 4 H- <b>2,</b> <b>3</b> -benzodiazepin- 4 -one (<b>2,</b> <b>3</b> -BZ- <b>2)</b> and <b>2,</b> <b>3</b> -BZ- <b>2</b> M (<b>3</b> -methyl derivative of <b>2,</b> <b>3</b> -BZ- <b>2)</b> which showed comparable activity. Thirty minutes after i. p. administration of <b>2,</b> <b>3</b> -benzodiazepines, the rank order of potency for anticonvulsant activity against clonus was <b>2,</b> <b>3</b> -BZ- <b>2</b> > GYKI 52466 > <b>2,</b> <b>3</b> -BZ- <b>2</b> M > <b>2,</b> <b>3</b> -BZ- 1 > <b>2,</b> <b>3</b> -BZ- <b>3,</b> > <b>2,</b> <b>3</b> -OBZ- 1, > <b>2,</b> <b>3</b> -OBZ- <b>2</b> <b>2,</b> <b>3</b> -OBZ- 3. The intracerebroventricular (i. c. v.) injection of aniracetam on it own (12. 5 - 100 nmol/mouse) had no convulsant activity, but it reversed the anticonvulsant effects of some <b>2,</b> <b>3</b> -benzodiazepines. In particular, the pharmacological actions of GYKI 52466, <b>2,</b> <b>3</b> -BZ- <b>2</b> and <b>2,</b> <b>3</b> -BZ- <b>2</b> M, which {{proved to be the}} most potent <b>2,</b> <b>3</b> -benzodiazepine derivatives as anticonvulsants, were significantly reduced by an i. c. v. pretreatment with aniracetam (50 nmol/mouse). Concomitant treatment with aniracetam (50 nmol/mouse) shifted to the right the dose-response curves and significantly increased the ED 50 values for GYKI 52466, <b>2,</b> <b>3</b> -BZ- <b>2</b> and <b>2,</b> <b>3</b> -BZ- <b>2</b> M. After 30 min pretreatment <b>2,</b> <b>3</b> -BZ- <b>2</b> showed a similar potency to GYKI 52466 in antagonizing seizures induced by i. c. v. administration of alpha-amino- 3 -hydroxy- 5 -methyl- 4 -isoxazolepropionic acid (AMPA), thus suggesting a clear involvement of AMPA receptors in the anticonvulsant activity of these compounds. In addition, <b>2,</b> <b>3</b> -BZ- <b>2</b> and <b>2,</b> <b>3</b> -BZ- <b>2</b> M showed anticonvulsant properties longer lasting than GYKI 52466...|$|R
5000|$|In theory, {{the message}} is then {{converted}} to its coordinates in this grid; in practice, {{it is more convenient}} to write the triplets of trits out in a table, like so:Then the coordinates are written out vertically beneath the message: T R E A T Y E N D S B O E R W A R [...] <b>2</b> 1 <b>3</b> <b>3</b> <b>2</b> 1 <b>3</b> <b>3</b> <b>2</b> 1 1 1 <b>3</b> 1 <b>2</b> <b>3</b> 1 3 3 1 1 3 3 1 1 1 <b>2</b> <b>3</b> <b>2</b> <b>3</b> 1 1 <b>2</b> <b>3</b> 1 1 <b>3</b> <b>2</b> 1 <b>2</b> <b>3</b> <b>3</b> 1 <b>2</b> <b>2</b> <b>3</b> <b>3</b> 1 1 <b>2</b> <b>3</b> <b>2</b> 2 3They are then read out in rows: ...|$|R
5000|$|... 2, 1093, 11, 1093, <b>2,</b> 66161, 5, <b>3,</b> <b>2,</b> <b>3,</b> 71, 2693, <b>2,</b> 29, 29131, 1093, <b>2,</b> 5, <b>3,</b> 281, <b>2,</b> 13, 13, 5, <b>2,</b> <b>3,</b> 11, <b>3,</b> <b>2,</b> 7, 7, 5, <b>2,</b> 46145917691, <b>3,</b> 66161, <b>2,</b> 17, 8039, 11, <b>2,</b> 23, 5, <b>3,</b> <b>2,</b> <b>3,</b> ...|$|R
5000|$|... 0, 1, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>3,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> <b>3,</b> 0, 0, <b>3,</b> 5, <b>2,</b> 0, 0, 7, 5, 0, 2, 7, 2, 0, <b>2,</b> 0, <b>3,</b> 0, 0, <b>3,</b> 0, 0, <b>2,</b> <b>3,</b> 0, 0, 6, 0, 3, 0, 0, 5, 5, 0, 3, <b>3,</b> 0, 0, <b>2,</b> 5, 0, 0, 0, <b>3,</b> <b>2,</b> 0, <b>2,</b> <b>3,</b> 0, 0, 0, 0, 2, 0, 0, 0, 7, 0, 5, 5, 0, ...|$|R
40|$|Contents Preface xiii I Background 1 1 Introduction <b>3</b> <b>2</b> ISO Standard Z 5 2. 1 History {{and current}} status 5 2. 1. 1 Z: {{the early years}} 5 2. 1. 2 The need for a change 6 <b>2.</b> 1. <b>3</b> Standardisation 7 <b>2.</b> 1. 4 Aims of this chapter 7 2. 2 Changed {{features}} of Standard Z 8 <b>2.</b> <b>3</b> Improvements 8 <b>2.</b> <b>3.</b> 1 Sections 8 <b>2.</b> <b>3.</b> <b>2</b> Mutually-recursive Free Types 9 <b>2.</b> <b>3.</b> <b>3</b> Operators 9 <b>2.</b> <b>3.</b> 4 Conjectures 9 <b>2.</b> <b>3.</b> 5 Binding Extensions and Tuple Selections 10 <b>2.</b> <b>3.</b> 6 Schemas as Expressions 11 <b>2.</b> <b>3.</b> 7 Empty Schemas 12 <b>2.</b> <b>3.</b> 8 Loose Generics 13 <b>2.</b> <b>3.</b> 9 Local Constant Declarations 13 <b>2.</b> <b>3.</b> 10 Axiom-parts as Predicates 14 <b>2.</b> <b>3.</b> 11 Soft Newlines 15 <b>2.</b> <b>3.</b> 12 Lexis of Words 15 <b>2.</b> <b>3.</b> 13 Toolkit 15 2. 4 Incompatibilities 16 2. 4. 1 Singleton Sets 16 ii Contents 2. 4. 2 Decorated References to Schemas 17 <b>2.</b> 4. <b>3</b> Decorated References to Generic Schemas 18 2. 4. 4 let on Predicates 18 2. 4. 5 Renaming on Theta Expressions 18 2. 4. 6 Underlined Infix Relations 19 2. 4. 7 Operator Precedences 19 2. 4. 8 Theta Expressions 21 2. 4. 9 Lexis of Words 21 2. 5 Subtle Changes 21 2. 5. 1 Qu...|$|R
40|$|The {{reaction}} of cobalt(II), nickel(II), copper(II) chlorides and bromides with thiophene- 3 -carboxaldoxime (3 TCOH) {{leads to a}} series of new complexes: [CoCl <b>2</b> (<b>3</b> TCOH) 4], [CoBr <b>2</b> (<b>3</b> TCOH) 4], [NiCl <b>2</b> (<b>3</b> TCOH) 4], [NiBr <b>2</b> (<b>3</b> TCOH) 4], [CuCl <b>2</b> (<b>3</b> TCOH) 4], [CuBr <b>2</b> (<b>3</b> TCOH) 2] respectively. The crystal structures of [CoBr <b>2</b> (<b>3</b> TCOH) 4], [NiBr <b>2</b> (<b>3</b> TCOH) 4] have been determined by X-ray diffraction methods showing octahedral complex species. In all complexes, the oxime functional group remains protonated and the coordination occurs through the nitrogen atom of the oxime moiety...|$|R
40|$|Contents Acknowledgments iii 1 Introduction 1 <b>2</b> Turbulence Simulation <b>3</b> <b>2.</b> 1 Preliminaries... [...] <b>3</b> <b>2.</b> 2 Multiscale Descriptions of Turbulence. [...] . 4 2. 2. 1 Reynolds Averaging [...] 4 2. 2. 2 Spatial Filtering [...] 6 <b>2.</b> <b>2.</b> <b>3</b> Variational Projection [...] 7 <b>2.</b> <b>3</b> Homogeneous Turbulence [...] . 8 <b>2.</b> <b>3.</b> 1 Direct Numerical Simulation.. [...] . 8 <b>2.</b> <b>3.</b> <b>2</b> Evaluating the Nonlinear Term [...] . 12 <b>2.</b> <b>3.</b> 3 Constructing an Initial Condition [...] 14 <b>2.</b> <b>3.</b> 4 Experimental Results [...] . 15 <b>2.</b> <b>3.</b> 5 Large Eddy Simulation [...] 17 <b>2.</b> <b>3.</b> 6 Simulating the CBC {{experiment}} [...] . 20 3 The Variational Multiscale Method 29 3. 1 Motivation [...] . 29 <b>3.</b> <b>2</b> Overview of the VMS-LES method.. [...] . 30 3. 3 Variational Formulation [...] ...|$|R
5000|$|... 2, 1093, 11, 1093, <b>2,</b> 66161, 5, <b>3,</b> <b>2,</b> <b>3,</b> 71, 2693, <b>2,</b> 29, 29131, 1093, <b>2,</b> 5, <b>3,</b> 281, <b>2,</b> 13, 13, 5, <b>2,</b> <b>3,</b> 11, <b>3,</b> <b>2,</b> 7, 7, 5, <b>2,</b> 46145917691, <b>3,</b> 66161, <b>2,</b> 17, 8039, 11, <b>2,</b> 23, 5, <b>3,</b> <b>2,</b> <b>3,</b> ... (The next term > 4.9Ã—1013) ...|$|R
5000|$|... 1, 1, 2, 1, <b>2,</b> 1, <b>3,</b> <b>2,</b> 1, <b>3,</b> <b>2,</b> 4, 1, <b>3,</b> <b>2,</b> 4, 1, <b>3,</b> <b>2,</b> 4, 1, <b>3,</b> 5, ...|$|R
